- Home
- CNTB vs TIL Comparison
CNTB vs TIL Comparison
Compare CNTB & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- TIL
- Stock Information
- Founded
- CNTB 2012
- TIL 2018
- Country
- CNTB United States
- TIL United States
- Employees
- CNTB N/A
- TIL N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- TIL Health Care
- Exchange
- CNTB Nasdaq
- TIL Nasdaq
- Market Cap
- CNTB 54.4M
- TIL 230.1M
- IPO Year
- CNTB 2021
- TIL 2021
- Fundamental
- Price
- CNTB $1.46
- TIL $23.87
- Analyst Decision
- CNTB Strong Buy
- TIL Buy
- Analyst Count
- CNTB 2
- TIL 5
- Target Price
- CNTB $7.50
- TIL $119.00
- AVG Volume (30 Days)
- CNTB 148.9K
- TIL 310.5K
- Earning Date
- CNTB 09-04-2025
- TIL 08-12-2025
- Dividend Yield
- CNTB N/A
- TIL N/A
- EPS Growth
- CNTB N/A
- TIL N/A
- EPS
- CNTB N/A
- TIL N/A
- Revenue
- CNTB $26,033,000.00
- TIL N/A
- Revenue This Year
- CNTB N/A
- TIL N/A
- Revenue Next Year
- CNTB N/A
- TIL N/A
- P/E Ratio
- CNTB N/A
- TIL N/A
- Revenue Growth
- CNTB N/A
- TIL N/A
- 52 Week Low
- CNTB $0.51
- TIL $9.85
- 52 Week High
- CNTB $1.60
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- CNTB 72.56
- TIL 46.54
- Support Level
- CNTB $1.05
- TIL $23.38
- Resistance Level
- CNTB $1.56
- TIL $26.91
- Average True Range (ATR)
- CNTB 0.13
- TIL 3.25
- MACD
- CNTB 0.04
- TIL -0.32
- Stochastic Oscillator
- CNTB 84.59
- TIL 31.75
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.